JP2019501125A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019501125A5 JP2019501125A5 JP2018525654A JP2018525654A JP2019501125A5 JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5 JP 2018525654 A JP2018525654 A JP 2018525654A JP 2018525654 A JP2018525654 A JP 2018525654A JP 2019501125 A5 JP2019501125 A5 JP 2019501125A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- halo
- heteroaryl
- substituted
- bicyclic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O Chemical compound *C1=CC(N(*)*)=I[n]2c1ncc2C(N*)=O 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562256784P | 2015-11-18 | 2015-11-18 | |
| US62/256,784 | 2015-11-18 | ||
| US201662404827P | 2016-10-06 | 2016-10-06 | |
| US62/404,827 | 2016-10-06 | ||
| PCT/US2016/062396 WO2017087590A1 (en) | 2015-11-18 | 2016-11-17 | Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019501125A JP2019501125A (ja) | 2019-01-17 |
| JP2019501125A5 true JP2019501125A5 (enExample) | 2019-12-26 |
| JP6843135B2 JP6843135B2 (ja) | 2021-03-17 |
Family
ID=57472068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018525654A Active JP6843135B2 (ja) | 2015-11-18 | 2016-11-17 | ＩＬ−１２、ＩＬ−２３および／またはＩＦＮα応答のモジュレーターとして有用なイミダゾピリダジン化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10479793B2 (enExample) |
| EP (1) | EP3377496B1 (enExample) |
| JP (1) | JP6843135B2 (enExample) |
| KR (1) | KR102782807B1 (enExample) |
| CN (1) | CN108473500B (enExample) |
| ES (1) | ES2828733T3 (enExample) |
| WO (1) | WO2017087590A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170333435A1 (en) | 2014-11-06 | 2017-11-23 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
| CA2966581A1 (en) | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
| HRP20240644T1 (hr) | 2014-11-06 | 2024-08-02 | Bial-R&D Investments, S.A. | Supstituirani pirazolo(1,5-a)pirimidini i njihova uporaba u liječenju medicinskih poremećaja |
| JP7046827B2 (ja) | 2016-04-06 | 2022-04-04 | リソソーマル・セラピューティクス・インコーポレイテッド | イミダゾ［１，５－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用 |
| SG11201808830YA (en) | 2016-04-06 | 2018-11-29 | Lysosomal Therapeutics Inc | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
| JP7164774B2 (ja) * | 2016-05-05 | 2022-11-02 | ビアル－アール・アンド・ディ・インベストメンツ・ソシエダーデ・アノニマ | 置換イミダゾ［１，２－ｂ］ピリダジン、置換イミダゾ［１，５－ｂ］ピリダジン、関連化合物、および医学的障害の治療におけるその使用 |
| US10836770B2 (en) | 2016-10-07 | 2020-11-17 | Bristol-Myers Squibb Company | Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or INF alpha responses |
| KR102611856B1 (ko) * | 2016-11-17 | 2023-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제 |
| JP7216705B2 (ja) * | 2017-07-28 | 2023-02-02 | ニンバス ラクシュミ， インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用方法 |
| AR117398A1 (es) | 2018-03-12 | 2021-08-04 | Abbvie Inc | Inhibidores de la señalización mediada por tirosina cinasa 2 |
| JP7179161B2 (ja) * | 2018-09-10 | 2022-11-28 | イーライ リリー アンド カンパニー | 乾癬および全身性エリテマトーデスの処置に有用なピラゾロ［１，５－ａ］ピリミジン－３－カルボキサミド誘導体 |
| DK3870579T3 (da) | 2018-10-22 | 2025-01-02 | Alumis Inc | Tyk2-inhibitorer og anvendelser deraf |
| AR117177A1 (es) * | 2018-12-10 | 2021-07-14 | Lilly Co Eli | DERIVADOS DE 7-(METILAMINO)PIRAZOLO[1,5-A]PIRIMIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE IL-23 E INFa |
| TWI752400B (zh) * | 2019-01-07 | 2022-01-11 | 美商美國禮來大藥廠 | Il-17a抑制劑 |
| US11174264B2 (en) | 2019-01-23 | 2021-11-16 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| WO2020163778A1 (en) * | 2019-02-07 | 2020-08-13 | Ventyx Biosciences, Inc. | Tyk2 pseudokinase ligands |
| ES2987809T3 (es) * | 2019-03-05 | 2024-11-18 | Bristol Myers Squibb Co | Compuestos de imidazopiridazina útiles como moduladores de las respuestas de IL-12, IL-23 y/o IFN alfa |
| JP7586829B2 (ja) * | 2019-03-11 | 2024-11-19 | アルミス インコーポレイテッド | Ｔｙｋ２阻害剤およびその使用 |
| WO2021162944A1 (en) | 2020-02-12 | 2021-08-19 | Eli Lilly And Company | Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives |
| TWI810520B (zh) * | 2020-02-12 | 2023-08-01 | 美商美國禮來大藥廠 | 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物 |
| US12559496B2 (en) | 2020-04-30 | 2026-02-24 | Janssen Pharmaceutica Nv | Imidazopyrimidines as modulators of IL-17 |
| AR121959A1 (es) | 2020-04-30 | 2022-07-27 | Janssen Biotech Inc | Imidazopiridazinas como moduladores de il-17 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| CN115916207A (zh) * | 2020-08-20 | 2023-04-04 | 轶诺(浙江)药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| KR20230069984A (ko) * | 2020-09-16 | 2023-05-19 | 알루미스, 인크. | Tyk2 억제제 및 그의 용도 |
| US20240246944A1 (en) | 2021-03-16 | 2024-07-25 | Anrui Biomedical Technology (Guangzhou) Co., Ltd. | Amino heteroaryl compounds and compositions |
| CA3236262A1 (en) | 2021-10-25 | 2023-05-04 | Isaac Marx | Tyk2 degraders and uses thereof |
| CN118159524B (zh) * | 2022-01-28 | 2024-12-17 | 和记黄埔医药（上海）有限公司 | 咪唑并[1,2-b]哒嗪类化合物的中间体的合成方法 |
| WO2025168035A1 (zh) * | 2024-02-07 | 2025-08-14 | 合肥羿科医药有限公司 | 杂环类化合物、其药物组合物及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7176214B2 (en) | 2003-05-21 | 2007-02-13 | Bristol-Myers Squibb Company | Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| WO2008116064A2 (en) | 2007-03-21 | 2008-09-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful for the treatment of proliferative, allergic, autoimmune or inflammatory diseases |
| WO2009060197A1 (en) * | 2007-11-08 | 2009-05-14 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazopyridazines for use as protein kinase inhibitors |
| WO2009100375A1 (en) | 2008-02-06 | 2009-08-13 | Bristol-Myers Squibb Company | Substituted imidazopyridazines useful as kinase inhibitors |
| TWI491610B (zh) | 2008-10-09 | 2015-07-11 | 必治妥美雅史谷比公司 | 作為激酶抑制劑之咪唑并嗒腈 |
| EP2768509B1 (en) * | 2011-10-20 | 2017-03-22 | Glaxosmithkline LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| US8969565B2 (en) | 2012-03-09 | 2015-03-03 | Lexicon Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use |
| CN105992768B (zh) * | 2013-12-10 | 2018-04-20 | 百时美施贵宝公司 | 用作IL‑12、IL‑23和/或IFNα响应的调节剂的咪唑并哒嗪化合物 |
-
2016
- 2016-11-17 US US15/776,094 patent/US10479793B2/en active Active
- 2016-11-17 WO PCT/US2016/062396 patent/WO2017087590A1/en not_active Ceased
- 2016-11-17 JP JP2018525654A patent/JP6843135B2/ja active Active
- 2016-11-17 CN CN201680079065.7A patent/CN108473500B/zh active Active
- 2016-11-17 ES ES16805656T patent/ES2828733T3/es active Active
- 2016-11-17 EP EP16805656.2A patent/EP3377496B1/en active Active
- 2016-11-17 KR KR1020187016633A patent/KR102782807B1/ko active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019501125A5 (enExample) | ||
| JP2019530699A5 (enExample) | ||
| CY1123994T1 (el) | Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4 | |
| JP2016532715A5 (enExample) | ||
| JP2016516043A5 (enExample) | ||
| JP2016514159A5 (enExample) | ||
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| JP2017508782A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2017071634A5 (enExample) | ||
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| AR103064A1 (es) | Compuestos moduladores de fxr (nr1h4) | |
| EP3489232A3 (en) | Inhibitors of cyclin-dependent kinase 7 (cdk7) | |
| WO2015132799A3 (en) | Heterocyclic compounds | |
| JP2019522055A5 (enExample) | ||
| WO2017205536A3 (en) | Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer | |
| JP2016513696A5 (enExample) | ||
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| PH12020500327A1 (en) | Macrocyclic mcl-1 inhibitors and methods of use | |
| JP2014525420A5 (enExample) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2016507581A5 (enExample) | ||
| JP2015536947A5 (enExample) | ||
| JP2019535723A5 (enExample) | ||
| JP2018502048A5 (enExample) |